There is no quality assurance, no batch testing to pharmaceutical standards, and no clinical oversight when you are administering them on your own
doi:10.1056/NEJMoa1607141 Lau J, Bloch P, Schffer L, et al
GLP-1 drugs, a class of obesity and diabetes medications that includes Ozempic, Wegovy, Zepbound, and Mounjaro, are known to produce significant weight loss
Later meta-analyses also report small but significant reductions in body weight, BMI or fat mass, with effects more relevant in overweight or obese populations
In summary, human evidence on BPC-157 is scant and of low quality
the mechanistic insight that dataset can firmly support remains narrower than the breadth of the data implies